Scailyte Closes CHF6M Series A Funding
- Scailyte, a Basel, Switzerland-based med-tech company, raised CHF6M in Series A funding
- The round was led by a Swiss family office, Mirabaud bank and existing backers
- The company intends to use the funds to accelerate growth, expand operations and its business reach
- The company is a spin-off of ETH Zurich that combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology
- Its data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints
